| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Targeted reduction of HCT116 cell viability occurs with SSTC3 (0-1μM, 5 days). When the mutant CTNNB1 allele that causes its carcinogenic characteristics is removed, this ability is greatly diminished [1].
|
|---|---|
| ln Vivo |
A 24-hour course of SSTC3 therapy is possible [1]. In CD-1 mice, the intraperitoneal injection of SSTC3 (25 mg/kg, once daily for 8–12 days) suppresses the progression of colorectal cancer [1]. For a month, SSTC3 (10 mg/kg, intraperitoneally injected once daily) suppresses the growth of tumors caused by Apc mutations [1].
|
| Cell Assay |
Cell viability assay[1]
Cell Types: Colorectal cancer (CRC) cell line. Tested Concentrations: 0-1μM. Incubation Duration: 5 days. Experimental Results: diminished vitality. Western Blot Analysis[1] Cell Types: SW403 cells. Tested Concentrations: 100 nM. Incubation Duration: 15 minutes. Experimental Results: Increased beta-catenin phosphate levels. |
| Animal Protocol |
Animal/Disease Models: Fiveweeks old Apcmin mice [1].
Doses: 10 mg/kg. Route of Administration: IP 1 month. Experimental Results: Inhibition of Apc mutation-driven tumor growth. Animal/Disease Models: CD-1 mice. Doses: 25 mg/kg. Management: One IP per day for 8-12 days. Experimental Results: Inhibition of growth of HCT116 xenografts. attenuated the growth of this metastatic CRC PDX and Dramatically diminished the cell density of residual cancer. The expression of WNT biomarkers in this CRC PDX was diminished. |
| References |
| Molecular Formula |
C23H17F3N4O3S2
|
|---|---|
| Molecular Weight |
518.5313
|
| Exact Mass |
518.069
|
| CAS # |
1242422-09-8
|
| PubChem CID |
46912682
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
35
|
| Complexity |
823
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C(C(N([H])C2=NC(=C([H])S2)C2=C([H])C([H])=C([H])C([H])=N2)=O)=C([H])C=1[H])(N(C([H])([H])[H])C1C([H])=C([H])C(C(F)(F)F)=C([H])C=1[H])(=O)=O
|
| InChi Key |
HSFAATUFWDDUGW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H17F3N4O3S2/c1-30(17-9-7-16(8-10-17)23(24,25)26)35(32,33)18-11-5-15(6-12-18)21(31)29-22-28-20(14-34-22)19-4-2-3-13-27-19/h2-14H,1H3,(H,28,29,31)
|
| Chemical Name |
4-[methyl-[4-(trifluoromethyl)phenyl]sulfamoyl]-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide
|
| Synonyms |
SSTC-3; SSTC 3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~241.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9285 mL | 9.6426 mL | 19.2853 mL | |
| 5 mM | 0.3857 mL | 1.9285 mL | 3.8571 mL | |
| 10 mM | 0.1929 mL | 0.9643 mL | 1.9285 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
